Medical Device Investment Opportunity
corona blade
A Precision Electrosurgical Platform for a New Era of Open Surgery
$5M
Seed Round
$20M
Valuation Cap
20%
SAFE DISCOUNT
$50K
MINIMUM INVESTMENT
Open to Accredited Investors Only
INVESTMENTS IN PRIVATE SECURITIES CARRY SIGNIFICANT RISKS, INCLUDING THE POTENTIAL LOSS OF CAPITAL. CONSULT WITH YOUR ATTORNEY AND YOUR FINANCIAL PROFESSIONALS BEFORE MAKING INVESTMENT DECISIONS.
WATCH THE CORONA BLADE OVERVIEW
See how CoronaBlade is being developed to bring greater precision to open surgery while working with electrosurgical equipment hospitals already use.
Unlocking Houston Multifamily: Inside the Tiburon Value-Add Strategy
Join The Light Year Capital team and LSCRE for the Tiburon Apartments investor webinar.
JULY 14, 2026 | TUESDAY | 5:30 PM PST, 8:30 PM EST
via Zoom
WEBINAR STARTS IN:
Register For Live Webinar
Please fill out the form below to register.
INVESTMENT STRUCTURE
Seed-stage investment in Lamina Surgical through a SAFE financing round.
SEED ROUND
CoronaBlade | Lamina Surgical
Minimum INVESTMENT
$50,000
$5M
TOTAL RAISE
$20M
VALUATION CAP
20%
SAFE DISCOUNT
2030–2031
TARGET EXIT WINDOW
SAFE Structure: Investment through a Simple Agreement for Future Equity.
Use of Funds: Pre-clinical and GLP studies, CoronaBlade 510(k), limited launch, operating expenses, and continued Lux and Arx development.
QSBS Eligibility: Deal materials indicate potential QSBS eligibility, subject to applicable requirements and confirmation with a tax advisor.
PRIVATE MEDICAL DEVICE INVESTMENT OPPORTUNITY
Open to Accredited Investors Only
WHY CORONABLADE
CoronaBlade is a single-use precision electrosurgical instrument designed to reduce thermal spread compared with traditional Bovie electrosurgery.
It is generator-free, which means it is designed to plug into electrosurgical units hospitals already own. No new capital equipment is required. The device also incorporates smoke evacuation and illumination.
The near-term goal is FDA 510(k) clearance, with the current materials targeting Q4 2027.
CORONABLADE COMMERCIALIZATION ROADMAP
A staged path from product development and FDA clearance to launch, expansion, and the broader Lamina Surgical platform.
CoronaBlade 510(k)
Complete pre-clinical and GLP studies, verification testing, and prepare the CoronaBlade 510(k) submission, targeted for Q4 2027.
Limited Market Launch
Following clearance, begin a limited market release focused initially on wound care and electrophysiology, with broader commercialization planned thereafter.
Expand With Lux
Advance the Lux multi-mode imaging system, integrating visible, IR, fluorescence imaging, and 3D mapping into the surgical platform. FDA submission is targeted for 2028.
Build the Arx AI Platform
Develop Arx, a cloud-connected AI surgical copilot designed to provide real-time guidance, analytics, and recurring software revenue.
VIEW THE CORONABLADE INVESTMENT OVERVIEW
Why This Deal Stands Out?
A snapshot of the terms, traction, market opportunity, and growth roadmap behind the CoronaBlade investment.
01
$5M Seed Raise
Current financing round structured as a SAFE with a $20M valuation cap and 20% discount.
02
$50K Minimum
Minimum investment of $50,000 for participating investors.
03
Working Prototype
CoronaBlade has a working prototype, provisional patent filed, and freedom-to-operate confirmed.
04
Experienced Team
The team reports 23 prior FDA clearances and more than $300M in combined surgical-device exits.
05
$11B+ Market
The investment materials cite an $11B+ electrosurgery and imaging market with multiple potential clinical applications.
06
2030 to 2031 Exit Window
The current business plan identifies 2030 to 2031 as the targeted acquisition window, with prior comparable transactions cited in the materials.
OFFERING TIMELINE
SEPTEMBER 2026
SEED ROUND OPEN
2030–2031
TARGET EXIT WINDOW
HOW TO PARTICIPATE
A simple process to review the opportunity and indicate your interest in the CoronaBlade offering.
01
Soft Commit
Submit the short interest form and indicate your potential investment amount.
02
Review Investment Materials
Review the one-pager, full deal deck, and applicable offering documents.
03
Confirm Your Investment
Complete the required investment documentation and finalize your commitment electronically.
04
Investor Updates
Receive ongoing company and investment updates as the CoronaBlade platform progresses.
INVESTMENTS IN PRIVATE SECURITIES CARRY SIGNIFICANT RISKS, INCLUDING THE POTENTIAL LOSS OF CAPITAL. CONSULT WITH YOUR ATTORNEY AND YOUR FINANCIAL PROFESSIONALS BEFORE MAKING INVESTMENT DECISIONS.
OUR TEAM
Physician-led investment access supported by an experienced medical-device operating team.
Chirag Chaudhari, MD
Managing Partner & Founder
Chirag is an Emergency Medicine physician and a member of the Light Year Capital team presenting the CoronaBlade investment opportunity.
Frequently Asked Questions (FAQs)
Who can participate in the CoronaBlade offering?
This opportunity is intended for eligible accredited investors, subject to the applicable offering requirements and final investor approval.
What is the investment structure?
The current $5 million seed round is structured as a SAFE with a $20 million valuation cap and a 20% discount. The minimum investment is $50,000.
What returns are shown in the investment materials?
The deal deck includes illustrative exit scenarios based on hypothetical exit values of $150 million, $350 million, and $700 million. These scenarios are examples only and are not guaranteed returns.
Will investors receive monthly distributions?
No monthly cash-flow distribution is presented in the investment materials. This is a seed-stage SAFE investment, not a cash-flowing real estate investment. Investor outcomes depend on the future performance of Lamina Surgical and a potential liquidity event.
What are the potential tax benefits?
The investment materials indicate potential QSBS eligibility, subject to applicable requirements and holding periods. Investors should confirm their individual eligibility with their own tax advisor.
How do I indicate my interest?
Click “Soft Commit Now” and complete the short interest form. After that, you can review the investment materials and complete the final investment documentation if you decide to proceed.
What are the risks?
Private investments involve significant risk, including potential loss of capital and limited liquidity. Investors should review the offering materials and consult their legal, tax, and financial advisors before investing.
This information is provided for informational purposes only and does not constitute an offer or solicitation to purchase securities. Any offering will be made only through the applicable offering documents and subject to investor eligibility and approval. Investors should review all investment materials and conduct their own due diligence before investing.
Private investments involve significant risk, including the potential loss of capital and limited liquidity. Forward-looking statements, projections, potential exit values, and illustrative returns are not guarantees of future performance. Investors should consult their own legal, tax, and financial advisors before making an investment decision.
DEVELOPMENT MODEL REDUCES RISK & INCREASES FAVORABLE FINANCING
This “No Frills” project phase is a set of five 14-plex buildings (with the option to deliver additional units). By excluding traditional amenities like a gym and underground parking, we build faster, and then lease up as each building is completed.
Quicker lease-up means faster cash flows
Faster cash flows mean better finance and refinance options
“No Frills” approach nets rents slightly under market premiums but with greatly reduced construction time and cost (due to area demand and careful submarket selection)